Pharmaceuticals, Biotechnology and Life Sciences
Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, has reported its audited annual results for the year ended December 31, 2016.
Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, has appointment Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017.
Kiadis Pharma has started its phase III trial with its major products for blood cancer hematopoietic stem cell transplantation (HSCT) ATIR101.
Kiadis Pharma has announced an update on the second dose Phase II trial with ATIR101 (CR-AIR-008 ).
Kiadis Pharma did not generate any revenues in the first nine months of 2015, the company said Friday.